Legend Biotech Corp ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
15analysts covering
FY EPS (est.)
-$0.01next fiscal year
Monitoring Framework
Key Performance Indicators
CARVYKTI Net Trade Sales Quarterly597MTarget: Continued sequential and year-over-year growth driven by earlier-line adoption
Manufacturing Success Rate Quarterly99.0%Target: Maintain high success rate to support commercial scaling
Median Turnaround Time (Vein-to-Vein) Quarterly29.0Target: Minimize turnaround time to optimize patient access
On-Time Order Releases Quarterly1.0Target: Maintain high reliability in supply chain delivery
Watch Items
- Competitive pressure from Gilead/ArcellxTrigger: Clinical data readouts or market share gains by competitors in multiple myelomaAction: Evaluate CARVYKTI's positioning and commercial execution strategies
- Safety signals such as IEC-associated Parkinsonism or other neurotoxicitiesTrigger: Increase in incidence rates of Grade 3+ neurotoxicities in real-world or clinical cohortsAction: Review CRS mitigation protocols and outpatient monitoring guidelines
- European IP litigation (e.g., 2seventy bio/BMS patent disputes)Trigger: Adverse court rulings or injunctions affecting European commercializationAction: Assess legal defense strategies and potential financial or operational impacts
Research as of 19 Jun 2026